Altium Capital Management’s Myriad Genetics MYGN Stock Holding History

Altium Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-180,000	Closed	-$4.18M	–	84
2023 Q1	$4.18M	Sell	180,000 -32,000	-15%	-$650K	2.32%	13
2022 Q4	$3.08M	Buy	212,000 +26,000	+14%	+$484K	1.56%	24
2022 Q3	$3.55M	Sell	186,000 -35,000	-16%	-$803K	1.3%	30
2022 Q2	$4.02M	Buy	221,000 +106,290	+93%	+$2.21M	1.61%	17
2022 Q1	$2.89M	Sell	114,710 -75,290	-40%	-$1.93M	0.97%	39
2021 Q4	$5.24M	Buy	190,000 +32,000	+20%	+$927K	1.45%	21
2021 Q3	$5.1M	Sell	158,000 -13,242	-8%	-$440K	1.34%	27
2021 Q2	$5.24M	Sell	171,242 -543	-0.3%	-$15.7K	1.21%	25
2021 Q1	$5.23M	Sell	171,785 -46,865	-21%	-$1.33M	1.45%	21
2020 Q4	$4.32M	Buy	+218,650	New	+$3.53M	1.61%	17

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Altium Capital Management's MYGN Position: Q2 2023 in Review

Altium Capital Management sold out of Myriad Genetics (MYGN) in Q2 2023, closing a stake of 180,000 shares — an estimated $4.18M sold.

Altium Capital Management first reported a position in MYGN in Q4 2020 and held it in 10 quarters. The position peaked at $5.24M in Q4 2021. 188 funds tracked by Wall St. Rank hold MYGN as of Q2 2023.

Altium Capital Management reported no remaining Myriad Genetics position as of Q2 2023 after selling out during the quarter.
Altium Capital Management sold 180,000 Myriad Genetics shares in Q2 2023, an estimated $4.18M.
Altium Capital Management first reported a position in Myriad Genetics in Q4 2020 and held it in 10 quarters.
Altium Capital Management's Myriad Genetics position peaked at $5.24M in Q4 2021.
188 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2023.

Based on Altium Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.